October 26, 2018, the registrant, Nexien BioPharma, Inc. entered into a Limited Liability Company Interest Purchase Agreement with the members of CRX Bio Holdings LLC. to acquire all of the membership interest in CRX in exchange for 11,000,000 restricted shares of Nexien common stock. Immediately after closing, Alex Wasyl, the CEO of CRX, was elected to serve as a director and the CEO of Nexien.

Alain Bankier, who had been serving as the interim CEO of Nexien, was elected to serve as Executive Chair of the Board of Directors and Chief Strategy Officer of Nexien. Richard Greenberg resigned his position as Chairman of the Board, but continues to serve on the Board. Other members of CRX will serve in executive capacities to be announced.

Mr. Wasyl, 29, was the co-founder of CRX. In addition, he has been the managing director of Elevated Life Sciences, a full service life sciences research and product development company, which he founded in February 2009.